Atrial fibrillation ablation in patients with arrhythmia-induced cardiomyopathy: a prospective multicentre study

Teba González-Ferrero1,2,3, Marco Bergonti4,5,6, José Nicolás López-Canoa3,7

  • 1Cardiovascular Area and Coronary Unit, University Clinical Hospital of Santiago de Compostela, Santiago de Compostela, Spain.

ESC Heart Failure
|August 18, 2023
PubMed

Insights

Arrhythmia-induced cardiomyopathy (AiCM) affects 17.56% of atrial fibrillation (AF) patients undergoing ablation. Persistent AF and chronic kidney disease predict AiCM, which improves after ablation with similar recurrence rates to non-AiCM patients.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Heart Failure Research

Background:

  • Atrial fibrillation (AF) can lead to arrhythmia-induced cardiomyopathy (AiCM).
  • Catheter ablation (CA) is a treatment option for AF, but its effect on AiCM requires further investigation.
  • Understanding predictors and outcomes of AiCM post-ablation is crucial for patient management.

Purpose of the Study:

  • To investigate the clinical and biochemical characteristics of patients with AF undergoing CA who develop AiCM.
  • To assess the long-term outcomes of CA in patients with and without AiCM.
  • To identify predictors of AiCM development and recurrence after CA.

Main Methods:

  • Prospective multicentre study of consecutive AF patients undergoing CA.
  • AiCM defined by heart failure development with AF and ≥10% improvement in left ventricular ejection fraction 6 months post-ablation.
  • Biomarker analysis (galectin-3, FABP4, sRAGE) in a subgroup of patients.

Main Results:

  • 17.56% of 769 AF patients developed AiCM.
  • Predictors of AiCM included persistent AF, male gender, left atrial volume, QRS width, smoking, and chronic kidney disease (CKD).
  • Biomarkers (sRAGE, FABP4, galectin-3) did not predict AiCM or recurrence. AF recurrence rates were similar between AiCM and non-AiCM groups (30.83% vs. 27.77%).

Conclusions:

  • AiCM development in AF patients undergoing ablation is associated with persistent AF and CKD.
  • Biomarker analysis did not predict AiCM or recurrence.
  • Patients with AiCM benefit from CA, showing improved left ventricular ejection fraction and comparable AF recurrence rates to those without AiCM.
Abstract

Related Concept Videos

Disturbances in Heart Rhythm01:28

Disturbances in Heart Rhythm

Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
1.0K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
16
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
16
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
19
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
42